t-test) than in benign tissue. The concentrations of linoleic acid (LA) and di-homo gamma linolenic acid (DGLA) in plasma and tissue were not different between the two groups of patients, but a significant reduction in arachidonic acid (ARA) (P<0.002, Mann-Whitney U-test) and docosapentaenoic acid (DPA) (P = 0.009) concentrations was observed in malignant tissue as compared to benign.
Patients with malignant prostatic disease also had a significantly higher concentration of oleic acid in phospholipids from both plasma and prostatic tissue. The stearic to oleic acid ratio was similar in plasma but was significantly reduced in malignant tissue (P = 0.006).
We suggest that the decreased arachidonic acid concentration in malignant tissue may be due to its increased metabolism, via the lipoxygenase and cyclooxygenase pathways to produce higher concentrations of eicosanoids, rather than an impairment in desaturase activity in situ.
The prostate gland in the elderly male is often affected by benign hyperplasia or malignant neoplasia. Prostatic malignancy is the third most frequent male cancer in the industrialised countries (Parkin et al., 1988) . Benign prostatic hyperplasia affects the majority of the male population by the age of 80 years, with around 10% requiring surgical intervention (Birkoff, 1983) . Despite the importance of these diseases, both in terms of mortality and morbidity, the aetiology remains unknown and there is no satisfactory treatment for hormone relapsed prostatic cancer. Recent epidemiological studies on carcinoma of the prostate gland report a positive relationship between the consumption of dietary fats and development of prostatic cancer in 32 countries (Shennen et al., 1974) . This association has been confirmed by almost all case controlled studies published to date (Rotkin et al., 1977; Schuman et al., 1977; Graham et al., 1983; Snowdon et al., 1984) . These observations have lead to the suggestion that a high dietary fat intake may be a contributing factor in the initiation or development of this tumour (Blair et al., 1978) .
It is well established that the growth and development of the prostate gland requires the presence of sex hormones, particularly testosterone. Testosterone may act by altering the metabolism of fat in the body (Pollard et al., 1986) and has been shown to regulate the synthesis, release and metabolism of prostaglandins (PGs) in the prostate gland (Klein et al., 1983; Cavanaugh et al., 1980) . The synthesis of prostaglandins is initiated by the release of esterified arachidonic acid (ARA, C20:4n-6) from cellular phospholipids by phospholipase(s). ARA is the desaturated product of dietary linoleic acid (LA, C18:2n-6), an EFA which is the most prevalent polyunsaturated fatty acid component of membrane phospholipids (Gottard, 1986) . The amount and composition of EFA in the membrane phospholipids can be modified by endocrine status and by both the amount and type of dietary fat ingested (Wahle, 1983; Howard, 1986) ; the presence of unusual fatty acids (i.e. trans or cis isomers of usual fatty acids) may affect EFA metabolism by inhibiting the desaturation pathways (Holman, 1986 ).
Cancer cells have been reported to have reduced concentrations of desaturated metabolites of LA such as gamma linolenic acid (GLA, C18:3n-6) and di-homo gamma linolenic acid (DGLA, C20:3n-6) (Bartoli et al., 1980; Begin et al., 1986 ) probably because of a reduced activity of delta-6 desaturase. This may cause an increase in LA concentrations with decreased conversion to ARA (Cheesman et al., 1984; Burns et al., 1987) . However, a recent report (Neoptolemos et al., 1991) has shown an increase in ARA and docosahexaenoic acid (DHA, C22:6n-3) concentrations in human colorectal cancer tissue. They suggest this increase is possibly due to a combination of enhanced desaturation of ARA precursor, reduced lipid peroxidation, and the increased production of prostanoids such as PGE2. Clearly the question of whether cancer cells and malignant tissues have increased or decreased desaturase activities is controversial at present. The possibility that reported differences in desaturase activity reflect different types of tumours or differences between cell lines and tissues also requires clarification.
We report the fatty acid composition in plasma and prostatic tissue phospholipids of the patients with benign and malignant prostatic disease.
Materials and methods

Patients and samples
Patients admitted for prostatic surgery, for benign or malignant disease, were recruited to the study and written consent was obtained.
Blood samples were taken from fasting patients. Ten ml venous blood was dispensed in vacutainer tubes pretreated with EDTA (Becton & Dickinson, France), and centrifuged at 800 g for 30 min within 15 min of collection. Two ml aliquots of plasma were placed in separate tubes and stored immediately at -70°C.
Prostatic tissue was collected fresh at operation and was immediately frozen in liquid nitrogen and then stored at -70°C until analysed.
Lipid analysis Total lipid extraction from all samples, including plasma and tissues, was carried out according to the method of Folch et al. (1975) . All solvents used were AnalaR grade and had 0.005% BHT added as an antioxidant agent.
The phospholipids and neutral lipids of the total lipid extract were separated from each other by sequential elution with different ratios of chloroform and methanol through 'Sep-Pak' silica cartridges under vacuum (Waters Associates, USA). Only the phospholipids were analysed further as they are the most sensitive indicators of essential fatty acid changes. 2MeC16:0 as 5% of the weight of phospholipids was added as internal standard. Samples were methylated under reflux for 2 h in a heating block at 90°C with 2 ml methanolic hydrochloric acid. Fatty acid methyl esters (FAME) were extracted into di-ethyl ether, washed until neutral to litmus, taken to dryness under a stream of nitrogen, dissolved in 2 ml of hexane: di-ethyl ether (95:5 v/v) and eluted through heat activated silicic acid columns to remove contaminants and the resulting FAME analysed by capillary gas chromatography.
Analysis of FAME FAME were analysed on a Pye Unicam, PU-4500 (Phillips, The Netherlands) gas chromatograph. Samples were injected onto a 25 m wall coated open tubular (WCOT) fused silica, CP Sil-5 SB, capillary column with 0.22mm internal diameter (Chrompack International, The Netherlands). Helium, at a flow rate of 1 ml min-', was used as the carrier gas and pre-column split ratio was 92:1. Rise in column temperature was programmed at 180'C for 8 min, then 6°C min-' to 230°C and stable at 230°C for 7 min. Total run time for each sample was programmed to 25 min. Both injector and detector temperature was fixed at 300°C. FAME concentrations were determined using a flame ionisation detector, peaks were plotted and analysed on an SP4270 (Spectra-Physics, USA) plotter/integrator and were identified by their 'on column' retention time compared to those of known standards. Quantitation was done by comparing the area % of each FAME peak on the chromatogram with that of internal standard of known weight.
Statistical analysis
The total lipids and phospholipid content of plasma and tissue in the two groups were compared using the unpaired t-test. The median values and interquartile ranges for each fatty acid were then calculated and compared using the Mann Whitney U-test.
Results
A total of 20 patients participated in the study. They were separated into either benign (n = 10) or malignant (n = 10) The fatty acid composition of plasma phospholipids in the benign and malignant group did not show any significant differences (Table I ) except for an increased oleic acid (C18:ln-9) concentration in the malignant group (P<0.03).
Tissue fatty acid concentrations (benign vs malignant)
The median concentrations of oleic acid were higher in malignant tissue when compared to benign tissue as is shown in Table II . While the concentrations of ARA and DPA were significantly higher (P <0.002 and P = 0.009 respectively) in benign prostatic tissue when compared to the malignant tissue, no significant differences were observed in the concentrations of any other fatty acid. Table III . No differences were seen in the ratio of these fatty acids in the plasma fatty acid pool of benign or malignant patients. However, this ratio is significantly lower in malignant than in benign prostatic tissue.
Discussion
To our knowledge, this is the first study which clearly indicates a variation of fatty acid composition in patients with benign and malignant prostatic disease.
The concentration of LA, the main essential fatty acid, was not different, in either plasma or prostatic tissue, between the two groups. This is despite the expected increased utilisation of La to build the cell membranes of rapidly dividing cancer cells. However, many reports have indicated that growing tumours are able to mobilise fatty acids from host stores to meet the increased demand for membrane growth (Kitada et al., 1980; Strain et al., 1980) . It has also been reported that a fat mobilising factor may be secreted by some tumour cells in order to ensure an adequate supply of fatty acids (Masuno et al., 1981) .
LA is further desaturated to form GLA by delta-6 desaturase. Further elongation of this fatty acid produced DGLA, the precursor of the I-series prostaglandins; delta-5 desaturation then results in the formation of ARA, the precusor of the II-series prostaglandins (Wahle, 1983 ). Delta-6-desaturase activity is reportedly reduced in cancer cells because of the low concentrations of GLA and DGLA found in these cells which were regarded as DGLA deficient (Horrobin, 1990) . In contrast to these observations, our results show no difference in the tissue concentrations of LA and DGLA between the two groups of patients. This does not suggest a reduction in delta-6 desaturase activity in prostatic cancer tissue. The possibility that cancer cell lines and cancer tissue may differ with regard to their desaturase activities is worthy of investigation. Determinations of desaturase activity per se, in microsomal preparations from benign and malignant tissues, rather than by the fatty acid end-product concentration in the tissue are currently being elucidated. Our suggestion that the delta-6 desaturase activities in malignant and benign prostatic tissue do not differ significantly is also at variance with the findings of Neoptolemos et al. (1991) who reported an increase in ARA and DHA concentrations in malignant colonic tissue and suggested this could be due, in part, to an enhancement desaturase (delta-6, delta-5) activity in human colonic cancer cells.
In the present studies, despite similar DGLA concentrations in malignant and benign prostatic tissue, ARA concentrations were significantly reduced in malignant tissue and DHA concentrations were again similar in both tissues. The lack of agreement between our observations and those of Neoptolemos et al. (1991) may be a reflection of the different types of tumour studied.
One possible mechanism to explain the significant decrease in ARA and DPA concentrations in malignant compared with benign tissue in the present studies would be an impairment of delta-5 desaturase enzyme activity in malignant tissues. Such an impairment has been postulated to occur in healthy Greenland Eskimos (Dyerberg et al., 1975; Sinclair, 1979) on the basis of their increased plasma DGLA and DHA concentrations when compared with those in Europeans. However, the concentrations of these fatty acids did not differ between tissues in the present studies. DGLA could be metabolised through the cyclooxygenase pathway to form PGE, but many cancers, including prostatic cancer, produce excessive amounts of PGE2 from ARA yet are unable to make PGE, (Easty et al., 1976 Wahle, 1991, unpublished data) . This lends support to the above explanation and suggests a possible central role for ARA in the aetiology of cancer.
Metabolism of ARA can proceed by pathways other than eicosanoid synthesis, for example by elongation to adrenic acid (C22:4n-6) followed by desaturation to DPA. This seems unlikely to be the explanation for the reduced ARA in malignant tissue given the observed reduction of DPA in this tissue.
Increased ARA metabolism via the cyclooxygenase pathway seems at present the most likely explanation for the reduced concentration of ARA in malignant tissue which we have demonstrated. PGE2, the main cyclooxygenase product of ARA is known to be a tumour promoter (Goodwin et al., 1983) and is often found in high concentrations in cancer cells (Hubbard et al., 1988) . This may have therapeutic implications as the cancer promoting effects of PGE2 can be inhibited by cyclooxygenase inhibitors such as Indomethacin (Kollmorgen et al., 1983) . Indeed feeding fish oils (n-3 fatty acids) to rats with prostatic tumours has been reported to be beneficial, as the desaturated metabolites of the n-3 family competitively inhibit the production of ARA derived eicosanoids (see Carroll, K., 1989 for recent review).
We found the ratio between stearic acid and oleic acid in malignant prostatic tissue to be significantly decreased. A reduction of stearic to oleic acid ratio in the platelets of patients with active malignancies (Copland et al., 1990) has previously been reported. Similar findings were observed in the peripheral blood cells of patients with chronic leukaemia (Apostolov et al., 1985) and in the circulating erythrocytes of patients with solid tumours (Wood et al., 1985) . The reason for the decreased stearic to oleic acid ratio in malignant tissue is not clear at present. It has been reported that the affinity of fatty acids for delta-6 desaturation is dependent on the number of double bonds. Linoleic acid, for example, has more affinity for delta-6 desaturase than oleic acid (Sinclair, 1984) . Thus the desaturation of LA abolishes further metabolism of oleic acid and oleic acid is desaturated to eicosatrienoic acid (C20:3n-9) only in EFA deficiency (Sinclair, 1984) . Reduced metabolism of oleic acid will obviously result in the reduction of stearic to oleic acid ratio.
It has been suggested that this reduced ratio in erythrocytes is a useful diagnostic marker for malignancies (Wood et al., 1985) . However, a similar decrease in stearic:oleic acid ratio has been observed in cells infected with Coxsackie and Herpes simplex type 2 viruses (Nozawa et al., 1982) and in patients with non-malignant diseases (Copland et al., 1991) . We conclude from these observations that the stearic:oleic acid ratio probably reflects abnormalities in fatty acid metabolism in general, and may not be a useful index in the diagnosis and postoperative monitoring of patients with cancer.
In conclusion, our results show that the concentration of arachidonic acid in malignant prostatic tissue is significantly lower than that found in benign tissue and we suggest that this may be due to increased ARA metabolism, possibly to form prostaglandins (as supported by our preliminary findings), high concentrations of which are often found in malignant tissue. Further investigation of the mechanisms which modify EFA metabolism in malignant as compared with benign prostatic tissue may clarify the role of the EFA/prostanoids in the aetiology of prostatic disease.
